ViroSeq HIV-1 Genotyping System

For In Vitro Diagnostic Use

The ViroSeq HIV-1 Genotyping System is intended for use in detecting HIV-1 genomic mutations that confer resistance to specific types of antiretroviral drugs, as an aid in monitoring and treating HIV infection.

View Ordering Information 

The ViroSeq HIV-1 Genotyping System can be used to:

  • Detect HIV-1 Subtype B viral resistance in plasma samples collected in EDTA with a viral load ranging from 2000 to 750,000 copies/mL
  • Genotype the entire HIV-1 protease gene from codons 1-99 and two-thirds of the reverse transcriptase (RT) gene from codons 1-335

Indication for Use

The indications for use encompass the following populations:

  • HIV-1 infected individuals at drug therapy failure (with increased viral load) before therapy switch
  • HIV-1 infected individuals at initial presentation, before initial drug therapy

ViroSeq HIV-1 Genotyping System Workflow*

Time-Saving ViroSeq HIV-1 Genotyping System Workflow

*For processing 12 samples on the ABI Prism® 3100/3130 Genetic Analyzers

Most Complete Genomic Coverage

ViroSeq HIV-1 Genotyping System coverage

Seven sequencing reactions with forward and reverse orientations achieve full codon coverage. Redundant sequencing primers provide multiple genomic coverage. 

Ordering Info

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No